Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to ...

A new AI tool that models how variations in peptides change T cell receptor binding could help design immunotherapies with ...

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell ...

T-cell Receptor Repertoire Analysis in the Context of Transarterial Chemoembolization Synergy with Systemic Therapy for Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology ...

We're excited to demonstrate that armoring the TCR-T cells with the chimeric switch receptor didn´t change the favorable safety profile but helped to overcome the immune inhibitory signal of TGF ...

New designer proteins created using an AI tool can selectively target peptide segments that bind to markers on diseased ...

About SCG101 SCG101, an autologous T-cell receptor (TCR) T cell therapy, is an investigational cell therapy product targeting a specific epitope of hepatitis B surface antigen (HBsAg).

T-cell receptor (TCR) sequencing provides a novel platform for insight into and characterization of intricate T-cell profiles, advancing the understanding of tumor immune heterogeneity.

Immunologists from UNIGE have discovered the previously unsuspected anti-tumor potential of CD4 T lymphocytes. An important ...